April 17–22, 2026 · San Diego · 2418 items
← KRAS / RAS targeting: from platform to Phase 3
64 people · 66 posts · 6 abstracts
Heat now 1·Peak in the comparable set 1 (Oct 23 10:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.
The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.
| Drug / trial | Readout | Setting |
|---|---|---|
| daraxonrasibdaraxonrasib | mOS 13.2 vs 6.7 mo, HR 0.40 | RASolute 302 · 2L mPDAC · Phase 3 |
| daraxonrasib ± GnPdaraxonrasib#PANCREATICCANCER#PDAC | mono ORR 47%; +GnP ORR 55%, DCR 90% | 1L mPDAC · Phase 1 |
The floor rewrote the question from “how long can G12C monotherapy last” to “who first makes first-line pancreatic cancer a standard.” daraxonrasib’s Phase 3 is still the only RAS-inhibitor overall-survival win.
Nina Dashti-Gibson, Amy L. Olex, Rachel K. Myrick, Alexa M. Barber, David C. Boyd, Emily K. Zboril, Katarzyna M. Tyc, Mikhail G. Dozmorov, Guang-Yu Yang, Nicholas T. Woods, Jose G. Trevino, J Chuck Harrell
Read the abstract →Kayla Tyskiewicz, Markus Hippich, Tristan Cates, Gervaise Henry, Gilad Silberberg, Nicole Spanburg, Madeline Westcott, Daniel Ciznadija, Michael Boice, Paul Heverly, Frank Smith, Marianna Zipeto, Stefano Cairo, Sebastian Brabetz
Read the abstract →Nataliya Tovbis Shifrin, Mariela Moreno Ayala, Cristina Blaj, Kevin Chen, Felix Mbuga, Joaquin Pechuan Jorge, Rashi Raghulan, Rich Liang, Linh Tran, Enrico Payson, Alice Kumamoto, Alexander McNamara, Marie Josette Catherine Menard, Michael Weiss, Lillian Seu, Elsa Quintana
Read the abstract →Ferdinandos Skoulidis, Kathryn C. Arbour, Sanjay Popat, Colin R. Lindsay, Hidehito Hironouchi, Gérard Zalcman, Alessandra Curioni-Fontecedro, Jarushka Naidoo, Adrianus J. de Langen, Lin Tao, Erica Su, Minoti Hiremath, Achim Rittmeyer, Melissa Johnson
Read the abstract →Eileen M. O'Reilly, Brian Wolpin, Shubham Pant, Joel Randolph Hecht, Jennifer Valerin, Dae Won Kim, Nilofer Azad, Kyaw Aung, Lin Tao, Sumit Kar, Hina Patel, Rashmi Vora, Aparna Hegde, Alexander Spira, Alexander Starodub, Benjamin Herzberg, Ignacio Garrido-Laguna
Read the abstract →Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal
Read the abstract →The FDA approved Revolution Medicines' daraxonrasib (RMC-6236, brand name Rasonque) on August 26 for patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or are not suited to multiple systemic therapies. The oral RAS(ON) multi-selective non-covalent inhibitor blocks interactions between wild-type and mutant RAS(ON) proteins and downstream effectors, and the FDA said the approval came 6.5 months ahead of schedule.
Why it matters: First RAS(ON) inhibitor approval worldwide, granted early for a hard-to-treat cancer.
The US FDA has approved Revolution Medicines' pan-RAS inhibitor daraxonrasib, brand name Rasonque, for previously treated metastatic pancreatic cancer (PDAC). The drug, the company's lead pipeline asset and the first RAS(ON) inhibitor approved worldwide, is active against G12, G13, Q61 and wild-type RAS. Late-stage trials are already underway in first-line, second-line and adjuvant pancreatic cancer settings.
Why it matters: First global approval of a RAS(ON) inhibitor class covers a hard-to-treat pancreatic cancer population.
The FDA approved Revolution Medicines' Rasonque (daraxonrasib), the first RAS(ON) inhibitor to reach the market, on August 26, months ahead of expectation. The once-daily tablet targets multiple forms of RAS protein, a key driver of tumor growth in most pancreatic cancer patients, and offers a new treatment option for the most common form of advanced pancreatic cancer, which arises from cells lining the pancreatic ducts.
Why it matters: First-ever RAS(ON) inhibitor approval, ahead of schedule, for a common pancreatic cancer setting.
The FDA approved Revolution Medicines' first-in-class RAS inhibitor Rasonque (daraxonrasib) on August 26 for adults with metastatic pancreatic ductal adenocarcinoma who have received at least one prior systemic therapy or are not suited for multi-drug systemic treatment. It is the first RAS-targeted therapy for the most common type of pancreatic cancer. The drug was reviewed under the FDA commissioner's national priority voucher pilot programme, and approval came one month after the application was accepted, 6.5 months ahead of the PDUFA goal date.
Why it matters: First RAS-targeted therapy approved for metastatic pancreatic ductal adenocarcinoma, reviewed 6.5 months early.
The US FDA has approved Revolution Medicines' daraxonrasib (Rasonque) for pancreatic adenocarcinoma patients who have received at least one prior systemic therapy or are not eligible for multiagent systemic therapy. It is the first broadly active RAS-targeted inhibitor to reach market, unlike the KRAS G12C-specific inhibitors sotorasib (Lumakras) and adagrasib (Krazati), which are approved only in NSCLC and colorectal cancer subsets.
Why it matters: First approval of a broadly active RAS inhibitor, in a hard-to-treat pancreatic cancer setting.
FDA approved Revolution Medicines' daraxonrasib (Rasonque) for pancreatic ductal adenocarcinoma, making it the first targeted therapy in the new RAS(ON) inhibitor class and the first new cancer drug cleared under the commissioner's national priority review voucher initiative. Revolution Medicines (NASDAQ:RVMD) is launching the drug immediately at a WAC of $39,800 for a 30-day supply.
Why it matters: First approval in a new drug class and first under FDA's new priority voucher programme, priced at launch.
The FDA has approved Revolution Medicines' Rasonque (daraxonrasib) as a second-line treatment for advanced pancreatic cancer, making it the first drug to target a genetic cause of the disease. In the pivotal trial supporting approval, the Rasonque arm achieved a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy. Andrew Ko, a gastrointestinal oncology specialist at UCSF, called it the biggest advance in pancreatic cancer treatment in decades.
Why it matters: The report gives second-line median overall survival of 13.2 versus 6.7 months, letting readers gauge the gain over standard chemotherapy.
The FDA has approved Revolution Medicines' Ras inhibitor daraxonrasib for metastatic pancreatic cancer. The decision follows data presented at the American Society of Clinical Oncology meeting in May. Daraxonrasib targets Ras in a disease setting with limited options.
Why it matters: FDA approval of a new Ras inhibitor for metastatic pancreatic cancer matters to clinicians and industry readers.
FDA has approved Revolution Medicines' Ras inhibitor daraxonrasib for metastatic pancreatic cancer. The approval is based on clinical data that drew a standing ovation at the American Society of Clinical Oncology (ASCO) annual meeting in May.
Why it matters: FDA approval based on standing-ovation data at ASCO in May provides regulatory backing for Ras inhibitors in pancreatic cancer.
The FDA approved Revolution Medicines' Rasonque (daraxonrasib), a once-daily RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or are not candidates for multiagent systemic therapy. In a 500-patient randomized trial, Rasonque improved median overall survival to 13.2 months versus 6.7 months on standard chemotherapy. The approval came 6.5 months ahead of the user fee deadline, under Breakthrough Therapy, Orphan Drug and Priority Review designations and the National Priority Voucher pilot program.
Why it matters: First-in-class RAS inhibitor approval gives a survival benefit in metastatic pancreatic adenocarcinoma, a high-mortality cancer with few options.
📣 #AACR26 HIGHLIGHTS 📌 ¡Ya disponible el nuevo episodio de #TooMoreGi by @DrAngelaLamarca!
📣 #AACR26 HIGHLIGHTS 📌 The new episode of #TooMoreGi by @DrAngelaLamarca is now available!
This is what makes Daraxonrasib more effective in pancreatic cancer than what we seen for decades.
Drug development is supposed to be linear.
GI-102 (Subprotocol C) – daraxonrasib + GnP in 1L mPDAC shows early signal 👇
New compound from @RevMedicines RM-055 disclosed at #AACR26
This is the second abstract I was waiting for the whole @AACR #AACR26
Waiting for two abstracts to be presented the whole @AACR #AACR26, this is one of them